The most serious side effect linked to Wegovy is a potential risk of thyroid C-cell tumors, which is significant enough to earn the drug’s only boxed warning from the FDA. Beyond that, gallbladder problems, stomach paralysis, and pancreatitis represent the most concerning complications, though they affect a small percentage of users. Most people experience milder gastrointestinal issues, but about 7% of patients in clinical trials found side effects severe enough to stop treatment entirely.
The Boxed Warning: Thyroid Tumors
Wegovy carries the FDA’s most prominent safety label, a boxed warning, for thyroid C-cell tumors. In animal studies, semaglutide caused thyroid tumors at doses comparable to what humans take, and the risk increased with higher doses and longer treatment. Whether this translates to humans remains unknown. No one has proven that Wegovy causes medullary thyroid carcinoma (MTC) in people, but no one has ruled it out either.
Because of this uncertainty, Wegovy is completely off-limits if you have a personal or family history of MTC or a condition called Multiple Endocrine Neoplasia syndrome type 2. Symptoms to watch for include a lump in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness.
Gallstones and Gallbladder Disease
Gallbladder problems are one of the more clearly established serious risks. In pooled data from eight clinical trials covering over 23,000 participants, 3% of people taking semaglutide experienced gallbladder complications compared to 2.2% on placebo. That translates to a 63% increased risk overall. Gallstones specifically were even more pronounced: 2.3% of semaglutide users developed them versus 0.9% on placebo, a 159% increase in risk.
Rapid weight loss itself is a known trigger for gallstones, so part of this risk may come from the weight loss rather than the drug directly. Either way, the practical result is the same. If you develop sudden pain in your upper right abdomen, especially after eating, that’s worth urgent medical attention.
Stomach Paralysis and Bowel Obstruction
Wegovy works partly by slowing how fast your stomach empties, which helps you feel full longer. In some people, this effect goes too far, leading to gastroparesis, a condition where the stomach essentially stops moving food through at a normal pace. A 2023 study found gastroparesis occurred at a rate of about 10 cases per 1,000 semaglutide users, and users were 3.7 times more likely to develop it compared to people on a different weight-loss medication.
Bowel obstruction is rarer but more dangerous. The same study found semaglutide users were 4.2 times more likely to experience it. Symptoms of gastroparesis include severe nausea, vomiting, bloating, and feeling full after only a few bites. Bowel obstruction typically involves intense cramping, inability to pass gas, and vomiting. Both require medical treatment.
Pancreatitis
Inflammation of the pancreas has been a long-standing concern with this class of drugs. In clinical trials, pancreatitis occurred in about 0.2% of semaglutide users, which was actually slightly lower than the 0.26% rate in placebo groups. However, a separate real-world study comparing semaglutide to another weight-loss drug found users were 9 times more likely to develop pancreatitis. That discrepancy likely reflects differences in study design and patient populations, but it keeps pancreatitis on the radar as a serious possibility. Severe, persistent abdominal pain that radiates to the back is the hallmark symptom.
Aspiration Risk During Anesthesia
Because Wegovy slows stomach emptying, food can remain in your stomach much longer than normal. This creates a real problem if you need surgery or any procedure requiring general anesthesia. Food still sitting in the stomach can be inhaled into the lungs during sedation, a dangerous event called pulmonary aspiration. The FDA updated labeling for all GLP-1 drugs in late 2024 to include this warning and ordered a study to figure out how long patients should stop the medication before surgery and how long they need to fast. If you’re scheduled for any procedure involving sedation, your anesthesiologist needs to know you take Wegovy.
What About Suicidal Thoughts?
Early reports raised concern that Wegovy might increase the risk of suicidal ideation. The FDA investigated thoroughly, analyzing 91 placebo-controlled trials involving nearly 108,000 patients and a separate real-world study of over 2.2 million users. The conclusion: no increased risk of suicidal thoughts, self-harm, depression, anxiety, or other psychiatric events. As of 2024, the FDA actually requested that the suicidal ideation warning be removed from Wegovy’s label entirely.
Kidney and Eye Concerns
For people with diabetes, rapid blood sugar improvement can temporarily worsen diabetic eye disease. This was observed in earlier semaglutide trials, though researchers believe it results from the speed of blood sugar correction rather than anything the drug itself does to the eyes. If you have diabetic retinopathy, your doctor will likely monitor you more closely early in treatment.
Kidney injury has appeared in some reports, typically linked to severe dehydration from persistent vomiting or diarrhea rather than direct kidney damage from the drug. Staying hydrated is especially important during the early months when GI side effects are most intense.
How Many People Quit Because of Side Effects
In pooled data from three major clinical trials, 6.8% of patients on Wegovy permanently stopped treatment due to adverse reactions, compared to 3.2% on placebo. Gastrointestinal problems were the primary reason, with 2.3% discontinuing specifically because of gut-related symptoms. The oral formulation showed similar numbers: 6.9% discontinued in the pill trial.
These dropout rates reflect the fact that side effects hit hardest during the dose escalation period. Wegovy is started at a low dose and gradually increased over about 16 weeks, stepping up every four weeks. This titration schedule exists specifically to let your body adjust and reduce nausea, vomiting, and diarrhea. If a particular dose level is too much, your prescriber can pause the escalation for an extra four weeks before moving up. Most people who make it through the ramp-up period find that side effects become manageable at the maintenance dose.